JAK2 V617F mutation is absent in chronic lymphocytic leukemia [5]

Leukemia and Lymphoma

Volumn 47, Issue 12, 2006, Pages 2657-2658

  Poulain, Stéphanie ^a   Merchez, Maud ^a   Daudignon, Agnès ^b   Simon, Marc ^c   Duthilleul, Patrick ^a   Morel, Pierre ^d  

^a CH de Valenciennes   (France)

^b Service d'Hématologie Immunologie Cytogénétique   (France)

^c Service d'Hématologie Clinique   (France)

^d Service d'Hematologie Clinique   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; JANUS KINASE 2; PHENYLALANINE; PROTEIN KINASE ZAP 70; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; VALINE;

ALLELE; CANCER GROWTH; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; LETTER; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

APOPTOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; FLOW CYTOMETRY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; JANUS KINASE 2; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MUTATION;

EID: 33845573026     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600925772     Document Type: Letter

References (12)

1. Caligaris-Cappio, F. (2003) Role of microenvironment in chronic lymphocytic leukeamia Br J Haematol, 123, pp. 380-388.
2. Chiorazzi, N and Rai, K and Ferranini, M. (2005) Chronic lymphocytic leukemia N Eng J. Med, 352, pp. 804-815.
3. James, C and Ugo, V and Casadevall, N and Constantinescu, S and Vainchenker, W. (2005) A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects Trends Mol Med, 11, pp. 546-554.
4. Martinez-Lostao, L and Briones, J and Forne, I and Martinez-Gallo, M and Ferrer, B and Sierra, J and (2005) Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia Leuk Lymphoma, 46, pp. 435-442.
5. Baxter, E and Scott, L and Campbell, P and East, C and Fourouclas, N and Swanton, S and (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet, 365, pp. 1054-1061.
6. Ishii, T and Bruno, E and Hoffman, R and Xu, M. (2006) Involvement of various hematopoietic cell lineages by the JAK V617F mutation in polycythemia vera Blood. Epub ahead of print, DOI 10.1182/ blood-2006-04-017392
7. Levine, R and Loriaux, M and Huntly, B and Loh, M and Beran, M and Stoffregen, E and (2005) The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic blastic leukemia or chronic lymphocytic leukemia Blood, 106, pp. 3377-3379.
8. Steensma, D and Dewald, G and Lasho, T and Powell, H and McClure, R and Levine, R and (2005) The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both 'atypical' myeloproliferative disorders and the myelodysplastic syndrome Blood, 106, pp. 1207-1209.
9. Lee, J and Soung, Y and Kim, S and Nam, S and Park, W and Lee, S and (2006) JAK2 V617F mutation is uncommon in non-Hodgkin lymphomas Leuk Lymphoma, 47, pp. 313-314.
10. Lu, X and Levine, R and Tong, W and Wernig, G and Pikman, Y and Zarnegar, S and (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2 V617F-mediated transformation Proc Natl Acad Sci USA, 102, pp. 18962-18967.
11. Frank, D and Mahajan, S and Ritz, J. (1997) B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT 3 constitutively phosphorylated on serine residues J Clin Invest, 100, pp. 3140-3148.
12. Steensma, D and McClure, R and Karp, J and Tefferi, A and Lasho, T and Powell, H and (2006) JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained Leukemia, 20, pp. 971-978.